Lv4
648 积分 2024-03-04 加入
Navigating the limits of ribociclib in early breast cancer: questions from the NATALEE trial
5天前
已关闭
P265: Clinicopathologic features, Adjuvant Treatment Patterns and Clinical Outcomes of HR+/HER2- Early Breast Cancer in China
5天前
已完结
Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?
18天前
已完结
Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER + Breast Cancer
20天前
已完结
Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China
25天前
已完结
Clinicopathologic features, Adjuvant Treatment Patterns and Clinical Outcomes of HR+/HER2- Early Breast Cancer in China
1个月前
已完结
Real-World Outcomes of Abemaciclib Dose-Escalation Strategy in High-Risk Early Breast Cancer
1个月前
已关闭
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
1个月前
已完结
Time-varying pattern of recurrence risk for Chinese breast cancer patients
1个月前
已完结
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience
2个月前
已完结
皖公网安备34019202002308
